SFX by Ex Libris Inc.

Title:	Protection against Experimental Allergic Encephalomyelitis
Source:	Nature [0028-0836] TEITELBAUM, DRORCA yr:1972

Basic

Full text

Full text available via Nature

Year:

Volume:

Issue:

Start Page:

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Johnson, K P P. "Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. 1995." Neurology 57.12 Suppl 5 (2002): 16-24.
description	2.	Johnson, K P P. "Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group." Neurology 45.7 (1995): 1268-76.
description	3.	Johnson, K P P. "Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. 1998 [classical article]." Neurology 57.12 Suppl 5 (2001): 46-53.
description	4.	Weber, Martin S S. "Type II monocytes modulate T cell–mediated central nervous system autoimmune disease." Nature medicine 13.8 (2007): 935-43.
description	5.	Gold, R. "The long-term safety and tolerability of high-dose interferon beta-1a in relapsing-remitting multiple sclerosis: 4-year data from the PRISMS study." European journal of neurology 12.8 (2005): 649-56.
description	6.	Filippi, M. "Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study." Lancet. Neurology 5.3 (2006): 213-20.
description	7.	Myers, J S S. "Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group." Neurology 50.3 (1998): 701-8.
description	8.	Broadley, Simon A. "Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 1 historical and established therapies. MS Neurology Group of the Australian and New Zealand Association of Neurologists." Journal of clinical neuroscience 21.11 (2014): 1835-46.
description	9.	Jacobs, L D D. "Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)." Annals of neurology 39.3 (1996): 285-94.
description	10.	Broadley, Simon A. "Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 1 Historical and established therapies." Journal of clinical neuroscience 21.11 (2014): 1835-1846.
description	11.	Comi, G. "European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Gla." Annals of neurology 49.3 (2001): 290-7.
description	12.	Caramanos, Z. "Evidence for use of glatiramer acetate in multiple sclerosis." Lancet. Neurology 4.2 (2005): 74-5.
description	13.	Kim, Ho Jin J. "Type 2 monocyte and microglia differentiation mediated by glatiramer acetate therapy in patients with multiple sclerosis." The journal of immunology 172.11 (2004): 7144-53.
description	14.	Johnson, K P. "Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability." Neurology 50.3 (1998): 701-708.
description	15.	Weber, Martin S S. "Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo." Brain 127.6 (2004): 1370-8.
description	16.	Francis, G. "PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS." Neurology 56.12 (2001): 1628-1636.
description	17.	Wingerchuk, Dean M M. "Multiple sclerosis disease-modifying therapies: Adverse effect surveillance and management." Expert Review of Neurotherapeutics 6.3 (2006): 333-346.
description	18.	Kappos, L. "Factors influencing long-term outcomes in relapsing-remitting multiple sclerosis: PRISMS-15." Journal of neurology, neurosurgery and psychiatry 86.11 (2015): 1202-7.
description	19.	Tejirian, T. "Sitz bath: where is the evidence? Scientific basis of a common practice." Diseases of the colon & rectum 48.12 (2006): 2336-40.
description	20.	Nagaraj, S. "Altered recognition of antigen is a mechanism of CD8(+) T cell tolerance in cancer." Nature medicine 13.7 (2007): 828-35.